Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

Key facts

Sponsor

University of California, San Francisco

Principal Investigator

Jon D Levine, MD, PhD

University of California, San Francisco

Intervention

nalbuphine plus naloxone(drug)

Enrollment

46 enrolled

Eligibility

18 years · All sexes

Timeline

2008 – 2010

Study locations (1)

• University of California, San Francisco, San Francisco, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Burning mouth syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07506018
  MucoLock™ for Treatment of Stomatitis
  Baptist Health South Florida
• RECRUITINGPHASE1, PHASE2NCT06726161
  Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
  RayzeBio, Inc.
• RECRUITINGEARLY PHASE1NCT07016555
  Burning Mouth Syndrome: Symptoms and Management
  University of Massachusetts, Amherst
• ACTIVE NOT RECRUITINGNANCT07381361
  Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
  Lu Jiang
• RECRUITINGPHASE4NCT06040190
  Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
  Federal University of Minas Gerais
• RECRUITINGNCT05819697
  Reducing Patient Memory Recall in the Burning Mouth Patient Population
  University of Pennsylvania

See all trials for Burning mouth syndrome →